Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Long-Term Deferred Tax (2020 - 2024)

Lexaria Bioscience's Long-Term Deferred Tax history spans 4 years, with the latest figure at $9.6 million for Q3 2023.

  • For Q3 2023, Long-Term Deferred Tax rose 21.81% year-over-year to $9.6 million; the TTM value through Aug 2023 reached $9.6 million, up 21.81%, while the annual FY2023 figure was $9.6 million, 21.81% up from the prior year.
  • Long-Term Deferred Tax for Q3 2023 was $9.6 million at Lexaria Bioscience, up from $7.9 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $9.6 million in Q3 2023 and bottomed at $5.6 million in Q3 2020.
  • The 4-year median for Long-Term Deferred Tax is $7.2 million (2021), against an average of $7.4 million.
  • The largest annual shift saw Long-Term Deferred Tax grew 18.01% in 2021 before it increased 21.81% in 2023.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $5.6 million in 2020, then grew by 18.01% to $6.6 million in 2021, then grew by 19.28% to $7.9 million in 2022, then grew by 21.81% to $9.6 million in 2023.
  • Per Business Quant, the three most recent readings for LEXX's Long-Term Deferred Tax are $9.6 million (Q3 2023), $7.9 million (Q3 2022), and $6.6 million (Q3 2021).